MDM2 implications for potential molecular pathogenic therapies of soft-tissue tumors Review
| Authors: | Sun, S. Y.; Crago, A. |
| Review Title: | MDM2 implications for potential molecular pathogenic therapies of soft-tissue tumors |
| Abstract: | Murine double minute 2 (MDM2, gene name MDM2) is an oncogene that mainly codes for a protein that acts as an E3 ubiquitin ligase, which targets the tumor suppressor protein p53 for degradation. Overexpression of MDM2 regulates the p53 protein levels by binding to it and promoting its degradation by the 26S proteasome. This leads to the inhibition of p53’s ability to regulate cell cycle progression and apoptosis, allowing for uncontrolled cell growth, and can contribute to the development of soft-tissue tumors. The application of cellular stress leads to changes in the binding of MDM2 to p53, which prevents MDM2 from degrading p53. This results in an increase in p53 levels, which triggers either cell cycle arrest or apoptosis. Inhibiting the function of MDM2 has been identified as a potential therapeutic strategy for treating these types of tumors. By blocking the activity of MDM2, p53 function can be restored, potentially leading to tumor cell death and inhibiting the growth of tumors. However, further research is needed to fully understand the implications of MDM2 inhibition for the treatment of soft-tissue tumors and to determine the safety and efficacy of these therapies in clinical trials. An overview of key milestones and potential uses of MDM2 research is presented in this review. © 2023 by the authors. |
| Keywords: | mdm2; soft-tissue tumors |
| Journal Title: | Journal of Clinical Medicine |
| Volume: | 12 |
| Issue: | 11 |
| ISSN: | 2077-0383 |
| Publisher: | MDPI |
| Date Published: | 2023-06-01 |
| Start Page: | 3638 |
| Language: | English |
| DOI: | 10.3390/jcm12113638 |
| PROVIDER: | scopus |
| PMCID: | PMC10253559 |
| PUBMED: | 37297833 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding author is MSK author: Aimee Crago -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work